Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.70 |
| ▸ | TP53 | P04637 | 5/20 | 0.70 |
| ▸ | THRB | P10828 | 2/20 | 0.63 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 3/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29925013 | 1.00 | MAPT (0.70) | MAPTTP53THRBPOLBSMN1; SMN2 | |
| SCHEMBL24619745 | 0.92 | MAPT (0.83) | MAPTTP53THRBPOLBSMN1; SMN2 | |
| SCHEMBL30086031 | 0.92 | MAPT (0.83) | MAPTTP53THRBPOLBSMN1; SMN2 | |
| SCHEMBL24619236 | 0.91 | MAPT (0.71) | MAPTTP53THRBPOLBSMN1; SMN2 | |
| SCHEMBL30086042 | 0.91 | MAPT (0.71) | MAPTTP53THRBPOLBSMN1; SMN2 | |
| SCHEMBL24619882 | 0.90 | MAPT (0.69) | MAPTTP53THRBPOLBSMN1; SMN2 | |
| SCHEMBL29924843 | 0.90 | MAPT (0.69) | MAPTTP53THRBPOLBSMN1; SMN2 | |
| SCHEMBL29925486 | 0.89 | MAPT (0.70) | MAPTTP53THRBPOLBSMN1; SMN2 | |
| SCHEMBL24740806 | 0.89 | MAPT (0.70) | MAPTTP53THRBPOLBSMN1; SMN2 | |
| SCHEMBL31679249 | 0.88 | MAPT (0.67) | MAPTTP53THRBPOLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024010762-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | ANIMA BIOTECH INC. (US) | 2024-01-11 | — | — | WO | disclosed |
| US-20220370431-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | ANIMA BIOTECH INC. (US) | 2022-11-24 | — | — | US | disclosed |
| WO-2022150316-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | ANIMA BIOTECH INC. (US) | 2022-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220370431-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | MYC, MYCBP, MYCBP2 | MAPT 3215/4885TP53 96/4885THRB 2134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.